Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Evelo Biosciences Inc

Healthcare US EVLO

0.0001USD
0.00(0%)

Last update at 2026-06-02T20:00:00Z

Day Range

0.00050.0005
LowHigh

52 Week Range

0.00010.002
LowHigh

Fundamentals

  • Previous Close 0.0001
  • Market Cap0.00190M
  • Volume133
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-69.67400M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-3.91

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -81.44400M -113.59700M -121.74800M -93.25700M -85.47200M
Minority interest - - - - -
Net income -82.34900M -114.52700M -122.17600M -93.66600M -85.66200M
Selling general administrative 20.85M 29.91M 31.75M 22.27M 23.23M
Selling and marketing expenses - - - - -
Gross profit - - - - -
Reconciled depreciation 1.56M 2.06M 2.22M 2.03M 1.76M
Ebit - -108.46600M -115.39600M -93.91200M -88.12100M
Ebitda - -108.40500M -114.91000M -91.88600M -86.35700M
Depreciation and amortization - 0.06M 0.49M 2.03M 1.76M
Non operating income net other - - -6.35200M -1.37100M 1.07M
Operating income -74.33500M -108.46600M -115.39600M -91.88600M -86.35700M
Other operating expenses - 108.47M 115.40M 91.89M 86.36M
Interest expense 5.48M 4.67M 3.61M 2.11M 1.05M
Tax provision 0.91M 0.93M 0.43M 0.41M 0.19M
Interest income - - - - 1.05M
Net interest income -5.47900M -4.67200M -3.61200M -2.10900M 1.05M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - 0.93M 0.43M 0.41M 0.19M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 74.33M 108.47M 115.40M 91.89M 86.36M
Cost of revenue - - - - -
Total other income expense net -1.63000M -5.13100M -6.35200M -1.37100M 0.89M
Discontinued operations - - - - -
Net income from continuing ops -82.34900M -114.52700M -122.17600M -93.66600M -85.47200M
Net income applicable to common shares - -114.52700M -122.17600M -93.66600M -85.47200M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 64.44M 87.87M 90.64M 90.92M 159.87M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 3.63M 2.58M 2.12M 3.18M 3.70M
Total liab 69.43M 79.20M 60.15M 30.72M 22.92M
Total stockholder equity -4.99200M 8.67M 30.48M 60.20M 136.95M
Deferred long term liab - 7.50M - 1.15M 1.07M
Other current liab 0.87M 0.74M 0.46M 9.12M 7.72M
Common stock 0.11M 0.05M 0.05M 0.03M 0.03M
Capital stock 0.11M 0.05M 0.05M 0.03M 0.03M
Retained earnings -529.22200M -414.69500M -292.51900M -198.85300M -113.38100M
Other liab 8.16M 7.50M 0.28M 1.35M 1.38M
Good will - - - - -
Other assets 1.16M 1.31M 12.18M 1.57M 1.32M
Cash 47.94M 68.44M 68.86M 77.83M 147.92M
Cash and equivalents - - - - -
Total current liabilities 12.39M 17.36M 19.83M 9.74M 9.23M
Current deferred revenue 7.50M 13.07M -2.13700M - -
Net debt 3.20M -12.14800M -28.82000M -58.19900M -135.61400M
Short term debt 2.26M 1.95M 1.67M - -
Short long term debt - - - - -
Short long term debt total 51.14M 56.29M 40.04M 19.63M 12.30M
Other stockholder equity 524.12M 423.31M 322.96M 259.02M 90.45M
Property plant equipment 11.71M 6.62M 7.48M 8.34M 6.92M
Total current assets 51.57M 71.03M 68.86M 77.83M 147.92M
Long term investments - - - - -
Net tangible assets -4.99200M 8.67M 30.48M 60.20M 136.95M
Short term investments - - - 0.00000M 54.82M
Net receivables - - - - -
Long term debt 43.61M 46.56M 30.05M 19.63M 12.30M
Inventory - - - - -
Accounts payable 1.76M 1.60M 19.83M 9.74M 9.23M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - -90.92000M -0.01800M
Additional paid in capital - - - - -
Common stock total equity - 0.05M 0.05M 0.03M 0.03M
Preferred stock total equity - - - - -
Retained earnings total equity - -414.69500M -292.51900M -198.85300M -113.38100M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 1.16M 1.31M 3.55M 4.75M 5.02M
Deferred long term asset charges - - - - -
Non current assets total 12.87M 16.84M 21.78M 13.09M 11.95M
Capital lease obligations 7.52M 9.74M 11.66M - -
Long term debt total - 46.56M 30.05M 19.63M 12.30M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments 0.27M -0.62200M -1.48100M -1.31500M 55.00M
Change to liabilities - 0.17M -2.88300M 8.48M 3.10M
Total cashflows from investing activities - -0.62200M -1.48100M -1.31500M 51.97M
Net borrowings - -3.12300M 14.78M 10.00M 4.48M
Total cash from financing activities 20.76M 81.66M 97.54M 65.47M 4.99M
Change to operating activities - -9.83600M -5.59100M 6.93M 4.06M
Net income -82.34900M -114.52700M -122.17600M -93.66600M -85.47200M
Change in cash -52.15000M -20.65600M -0.66600M -8.91300M -15.01800M
Begin period cash flow 70.21M 69.75M 70.42M 79.33M 94.35M
End period cash flow 17.54M 49.10M 69.75M 70.42M 79.33M
Total cash from operating activities -73.70100M -101.23500M -96.72500M -73.06300M -71.98000M
Issuance of capital stock 29.17M 84.54M 81.75M 54.99M 0.00000M
Depreciation 1.56M 2.06M 2.22M 2.03M 1.76M
Other cashflows from investing activities - - 0.04M 0.00600M 0.00200M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - - 1.01M 55.47M 0.51M
Other cashflows from financing activities - 44.72M 15.79M 10.47M 19.99M
Change to netincome - 20.90M 19.32M 8.84M 8.42M
Capital expenditures 0.29M 0.62M 1.52M 1.32M 3.03M
Change receivables - - - - -
Cash flows other operating - - 6.80M 1.26M 0.37M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - -0.66600M -8.91300M -15.01800M
Change in working capital -11.78600M -9.66600M 2.07M 7.76M 3.47M
Stock based compensation 11.17M 15.16M 15.85M 8.47M 8.16M
Other non cash items 5.73M 5.74M 2.10M 2.35M 0.26M
Free cash flow -73.98800M -101.85700M -98.24400M -74.38400M -75.01200M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
EVLO
Evelo Biosciences Inc		 - -% 0.0001 - - - 3.51 -0.3877
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.75 1.73% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriasis . The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Evelo Biosciences Inc

600/700, One Kendall Square, Cambridge, MA, United States, 02139

Key Executives

Name Title Year Born
Dr. Balkrishan Gill Ph.D. Pres, CEO & Director 1965
Dr. Jonathan B. Zung Ph.D. Chief Devel. Officer 1965
Ms. Marella Thorell CFO & Treasurer 1967
Mr. Stephen J. Carriere VP & Chief Accounting Officer 1955
Dr. Chun Zhang Ph.D. Chief Technical Operations & Quality Officer NA
Dr. Mark Bodmer Ph.D. Chief Scientific Officer and Pres of R&D 1958
Ms. Kendra Sweeney Head of Investor Relations & Capital Markets NA
Ms. Jessica Cotrone VP & Head of Communications NA
Ms. Leslie Wardwell-Scott Ph.D. VP and Head of Corp. Devel. & Strategic Integration NA
Ms. Julie Carretero Chief People Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.